Roche’s Actemra Gets Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis Drugs Advisory Committee evaluates the interleukin-6 receptor inhibitor for rheumatoid arthritis July 29.